Maintenance Therapy for Inflammatory Bowel Disease

American Journal of Gastroenterology

Volumn 98, Issue 12 SUPPL., 2003, Pages

  Feagan, Brian G ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CORTICOSTEROID; FOLIC ACID ANTAGONIST; GLUCOCORTICOID; ICOSANOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEUKOTRIENE DERIVATIVE; LIPOXIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METOCLOPRAMIDE; NITROIMIDAZOLE; OLSALAZINE; OMEGA 3 FATTY ACID; ONDANSETRON; ORNIDAZOLE; PREDNISOLONE; PREDNISONE; PROSTAGLANDIN; PURINE ANTAGONIST; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; THROMBOXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLERGIC PNEUMONITIS; ASPERGILLOSIS; BRUISING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERANCE; ENDOSCOPY; ENTERITIS; FEVER; HIGH RISK POPULATION; HUMAN; LEUKOPENIA; LISTERIOSIS; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; MAINTENANCE THERAPY; META ANALYSIS; NAUSEA; OPPORTUNISTIC INFECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PURINE SYNTHESIS; RASH; RECURRENT DISEASE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT; SURGICAL RISK; TREATMENT FAILURE; TREATMENT WITHDRAWAL; TUBERCULOSIS; ULCERATIVE COLITIS;

EID: 0346785197     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjgastroenterol.2003.11.002     Document Type: Article

References (93)

1. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63.
2. Borely NR, Mortensen NJ, Jewell DP. Preventing postoperative recurrence of Crohn's disease. Br J Surg 1997;84:1493-502.
3. Sachar DB. The problem of postoperative recurrence of Crohn's disease. Med Clin North Am 1990;74:183-8.
4. Lock MR, Farmer RG, Fazio VW, et al. Recurrence and reoperation for Crohn's disease: The role of disease location in prognosis. N Engl J Med 1981;304:1586-8.
5. Michelassi F, Balestracci T, Chappell R, et al. Primary and recurrent Crohn's: Experience with 1379 patients. Ann Surg 1991;214:230-40.
6. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000;95:1849-50.
7. Brignola C, Campieri M, Farruggia P, et al. The possible utility of steroids in the prevention of relapses of Crohn's disease in remission. A preliminary study. J Clin Gastroenterol 1988;10:631-4.
8. Heimann TM, Greenstein AJ, Lewis B, et al. Prediction of early symptomatic recurrence after intestinal resection in Crohn's disease. Ann Surg 1993;218:294-9.
9. D'Haens GR, Gasparaitis AE, Hanauer SB. Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease. Gut 2001;36:715-7.
10. Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990;98:1123-8.
11. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994;106:643-8.
12. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-30.
13. Feagan BG, McDonald JWD, Koval JJ. Therapeutics and inflammatory bowel disease: A guide to the interpretation of randomized controlled trials. Gastroenterology 1996;110:275-83.
14. Summers RW, Switz DM, Sessions JT, Jr, et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979;77:847-69.
15. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984;86:249-66.
16. Wenckert A, Kristensen M, Eklund AE, et al. The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial. Scand J Gastroenterol 1978;13:161-7.
17. Ewe K, Herfarth C, Malchow H, et al. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: A multicenter trial. Digestion 1989;42:224-32.
18. Bergman L, Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. Scand J Gastroenterol 1976;11:651-6.
19. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997;112:1069-77.
20. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: A meta-analysis. Am J Gastroenterol 1994;89:2116-24.
21. Salomon P, Kornbluth A, Aisenberg J, et al. How effective are current drugs for Crohn's disease? A meta-analysis. J Clin Gastroenterol 1992;14:211-5.
22. Camma C, Giunta M, Rosselli M, et al. 5-Aminosalicylic acid in the maintenance of Crohn's disease: A meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.
23. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994;107:632-3.
24. Mahmud N, Kamm MA, Dupas JL, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: A double blind, parallel, randomised, multicentre study. Gut 2001;49:552-6.
25. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI Group. Gastroenterology 2000;118:264-73.
26. Feagan BG, McDonald JW. Mesalamine maintenance therapy for Crohn's disease. Gastroenterology 2001;120:585-6.
27. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology 1996;110:45-51.
28. Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996;39:82-6.
29. Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn's disease-results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998;12:175-83.
30. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: A randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748-54.
31. Sandborn W, Feagan B, Löfberg R, et al. Budesonide capsules prolong time to relapse in Crohn's disease patients with medically induced remission. Gastroenterology 2003;124(Suppl): A381 (abstract).
32. Ewe K, Bottger T, Buhr HJ, et al. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: A multicentre randomized placebo-controlled trial. German Budesonide Study Group. Eur J Gastroenterol Hepatol 1999;11:277-82.
33. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
34. Rutgeerts P. Strategies in the prevention of post-operative recurrence in Crohn's disease. Best Pract Res Clin Gastroenterol 2003;17:63-73.
35. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
36. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
37. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 1989;111:641-9.
38. Dayharsh GA, Loftus EV, Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-7.
39. Pearson C, May GR, Fick G, et al. Azathioprine for maintaining remission in Crohn's disease. The Cochrane Library. Oxford: The Cochrane Collaboration. Update Software, 1999.
40. Korelitz B, Hanauer S, Rutgeerts P, et al. Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: A 2-year multicenter trial. Gastroenterology 1998;14(suppl): A1011 (abstract).
41. Kozarek RA, Patterson DJ, Geland MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
42. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
43. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
44. McKendry RJ. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 1997;23:939-54.
45. Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:91-4.
46. Kremer JM, Alarcon GS, Lightfoot RW, Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.
47. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT 1 randomised trial. Lancet 2002;359:1541-9.
48. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-6.
49. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
50. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
51. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-100.
52. Gluck T, Linde HJ, Scholmerich J, et al. Anti-tumor necrosis factor therapy and listeria monocytogenes infection: Report of two cases. Arthritis Rheum 2002;46:2255-7.
53. Tai TL, O'Rourke KP, McWeeney M, et al. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) 2002;41:951-2.
54. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.
55. Baert F, Norman MR, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
56. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial. Gastroenterology 2003;124:917-24.
57. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumour necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71.
58. Teitelbaum JE, Allan Walker W. Review. The role of omega 3 fatty acids in intestinal inflammation. J Nutr Biochem 2001;12:21-32.
59. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334:1557-60.
60. Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-1993. Scand J Gastroenterol 1997;32:1005-12.
61. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
62. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International kidney biopsy registry of cyclosporine in autoimmune diseases. N Engl J Med 1992;326:1654-60.
63. Lashner BA. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 1995;24:467-74.
64. The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 1996;124:204-11.
65. Sutherland LR, Martin F. 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci 1987;32(suppl 12):64S-66S.
66. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicyclic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
67. Misiewicz JJ, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;i:185-8.
68. Azad Khan AK, Piris J, Truelove SC, et al. An optimum dose of sulfasalazine for maintenance treatment in ulcerative colitis. Gut 1980;21:232-40.
69. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicyclic acid for maintenance of remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library. Issue 4, 2003. Chicester, UK: John Wiley & Sons, Ltd.
70. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003;114:39-43.
71. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96:2929-33.
72. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002;97:3078-86.
73. McDonald JW. Balsalazide achieved symptomatic remission sooner than mesalamine for ulcerative colitis. ACP J Club 2003;138:71.
74. Hanauer SB. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis. Am J Gastroenterol 2003;98:215-6.
75. Farrell RJ, Peppercorn MA. Equimolar doses of balsalazide and mesalamine: Are we comparing apples and oranges? Am J Gastroenterol 2002;97:1283-5.
76. Sandborn WJ, Hanauer SB. Systematic review: The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17:29-42.
77. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: The role in distal ulcerative colitis. Am J Gastroenterol 2000;95:1628-36.
78. Brimblecombe R. Mesalazine: A global safety evaluation. Scand J Gastroenterol 1990;172(suppl):66.
79. Lennard-Jones JE, Misiewicz JJ, Connell AM, et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1965;191:188-9.
80. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: Final report on controlled therapeutic trial. BMJ 1974;4:627-30.
81. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-2.
82. Sood A, Kaushal V, Midha V, et al. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002;37:270-4.
83. Mantzaris GJ, Petraki K, Sfakianakis M, et al. A prospective, randomized trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steriod-dependent ulcerative colitis.
84. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21.
85. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
86. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9.
87. van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-31.
88. Thomas GAO, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995;332:988-92.
89. Shanahan F. Probiotics and inflammatory bowel disease: From fads and fantasy to facts and future. Br J Nutr 2002;88:S5-9.
90. McCarthy J, O'Mahony L, O'Callaghan L, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975-80.
91. Madsen KL. Inflammatory bowel disease: Lessons from the IL-10 gene-deficient mouse. Clin Invest Med 2001;24:250-7.
92. Kruis W. Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine.
93. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis, a randomised trial. Lancet 1999;354:635.